Azurity taps two banks for financing for Arbor purchase

By Sara Rosenberg

New York, Aug. 24 – Azurity Pharmaceuticals Inc. plans on getting new financing led by JPMorgan Chase Bank and Truist Securities Inc. to fund its acquisition of Arbor Pharmaceuticals Inc., according to a news release.

Arbor is being purchased from existing investors including JW Asset Management and KKR.

Closing is expected in September, subject to regulatory approvals.

Azurity is a Wilmington, Mass.-based specialty pharmaceutical company focusing on the needs of patients requiring customized, user-friendly drug formulations and dosage forms. Arbor is an Atlanta-based specialty pharmaceutical company marketing FDA-approved prescription products in the neuroscience, cardiovascular and institutional markets.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.